US Stock MarketDetailed Quotes

Pyxis Oncology (PYXS)

Watchlist
  • 1.660
  • -0.040-2.35%
Close Apr 17 16:00 ET
  • 1.750
  • +0.090+5.42%
Post 20:01 ET
104.30MMarket Cap-1.30P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Pyxis Oncology (PYXS) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
-14.17%13.86M
11.04M
0
2.82M
0
16.15M
0
0
0
16.15M
Operating revenue
-14.17%13.86M
--11.04M
--0
--2.82M
--0
--16.15M
--0
--0
--0
--16.15M
Cost of revenue
402.74%2.39M
2.39M
0
0
0
475K
0
0
0
475K
Gross profit
-26.81%11.47M
8.65M
0
2.82M
0
15.67M
0
0
0
15.67M
Operating expense
13.93%95.89M
41.04%26.95M
-1.23%23.46M
12.67%22.57M
7.70%22.91M
2.40%84.17M
7.53%19.11M
-6.31%23.75M
10.55%20.03M
1.54%21.28M
Selling and administrative expenses
-12.69%22.19M
3.01%5.23M
-5.99%5.65M
-10.56%5.44M
-28.82%5.87M
-22.05%25.42M
-17.52%5.08M
-43.63%6.01M
-9.67%6.08M
-8.90%8.25M
-General and administrative expense
-12.69%22.19M
3.01%5.23M
-5.99%5.65M
-10.56%5.44M
-28.82%5.87M
-22.05%25.42M
-17.52%5.08M
-43.63%6.01M
-9.67%6.08M
-8.90%8.25M
Research and development costs
25.45%73.7M
54.81%21.71M
0.38%17.81M
22.79%17.13M
30.82%17.04M
18.47%58.75M
20.82%14.02M
20.79%17.74M
22.49%13.95M
9.48%13.03M
Operating profit
-23.25%-84.42M
4.24%-18.3M
1.23%-23.46M
1.41%-19.75M
-308.81%-22.91M
16.67%-68.5M
-7.53%-19.11M
6.31%-23.75M
-10.55%-20.03M
73.25%-5.61M
Net non-operating interest income expense
-48.71%3.61M
-62.96%600K
-58.07%774K
-50.82%995K
-19.94%1.24M
6.17%7.04M
1.63%1.62M
8.14%1.85M
22.16%2.02M
-7.35%1.55M
Non-operating interest income
-48.71%3.61M
-62.96%600K
-58.07%774K
-50.82%995K
-19.94%1.24M
6.17%7.04M
1.63%1.62M
8.14%1.85M
22.16%2.02M
-7.35%1.55M
Other net income (expense)
114.28%2.58M
103.42%692K
-2.98%684K
-3.39%684K
-35.54%515K
-1,115.65%-18.04M
-3,615.63%-20.25M
17.89%705K
25.53%708K
2,002.63%799K
Special income (charges)
--0
----
----
----
----
---20.96M
----
----
----
----
-Less:Impairment of capital assets
--0
----
----
----
----
--20.96M
----
----
----
----
Other non- operating income (expenses)
-12.00%2.58M
-3.08%692K
-2.98%684K
-3.39%684K
-35.54%515K
64.75%2.93M
23.96%714K
17.89%705K
25.53%708K
2,002.63%799K
Income before tax
1.59%-78.24M
54.94%-17M
-3.77%-22M
-4.45%-18.07M
-549.82%-21.16M
-7.73%-79.5M
-141.94%-37.74M
8.01%-21.2M
-8.80%-17.3M
83.08%-3.26M
Income tax
164.05%1.39M
150.97%1.1M
0
283K
-2.16M
-2.16M
0
0
Net income
-2.96%-79.62M
49.10%-18.11M
-3.77%-22M
-6.09%-18.35M
-549.82%-21.16M
-4.80%-77.33M
-128.06%-35.57M
8.01%-21.2M
-8.80%-17.3M
83.08%-3.26M
Net income continuous Operations
-2.96%-79.62M
49.10%-18.11M
-3.77%-22M
-6.09%-18.35M
-549.82%-21.16M
-4.80%-77.33M
-128.06%-35.57M
8.01%-21.2M
-8.80%-17.3M
83.08%-3.26M
Minority interest income
Net income attributable to the parent company
-2.96%-79.62M
49.10%-18.11M
-3.77%-22M
-6.09%-18.35M
-549.82%-21.16M
-4.80%-77.33M
-128.06%-35.57M
8.01%-21.2M
-8.80%-17.3M
83.08%-3.26M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-2.96%-79.62M
49.10%-18.11M
-3.77%-22M
-6.09%-18.35M
-549.82%-21.16M
-4.80%-77.33M
-128.06%-35.57M
8.01%-21.2M
-8.80%-17.3M
83.08%-3.26M
Basic earnings per share
3.03%-1.28
50.85%-0.29
0.00%-0.35
-3.45%-0.3
-483.33%-0.35
28.65%-1.32
-78.79%-0.59
37.50%-0.35
29.27%-0.29
88.89%-0.06
Diluted earnings per share
3.03%-1.28
50.85%-0.29
0.00%-0.35
-3.45%-0.3
-483.33%-0.35
28.65%-1.32
-78.79%-0.59
37.50%-0.35
29.27%-0.29
88.89%-0.06
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue -14.17%13.86M11.04M02.82M016.15M00016.15M
Operating revenue -14.17%13.86M--11.04M--0--2.82M--0--16.15M--0--0--0--16.15M
Cost of revenue 402.74%2.39M2.39M000475K000475K
Gross profit -26.81%11.47M8.65M02.82M015.67M00015.67M
Operating expense 13.93%95.89M41.04%26.95M-1.23%23.46M12.67%22.57M7.70%22.91M2.40%84.17M7.53%19.11M-6.31%23.75M10.55%20.03M1.54%21.28M
Selling and administrative expenses -12.69%22.19M3.01%5.23M-5.99%5.65M-10.56%5.44M-28.82%5.87M-22.05%25.42M-17.52%5.08M-43.63%6.01M-9.67%6.08M-8.90%8.25M
-General and administrative expense -12.69%22.19M3.01%5.23M-5.99%5.65M-10.56%5.44M-28.82%5.87M-22.05%25.42M-17.52%5.08M-43.63%6.01M-9.67%6.08M-8.90%8.25M
Research and development costs 25.45%73.7M54.81%21.71M0.38%17.81M22.79%17.13M30.82%17.04M18.47%58.75M20.82%14.02M20.79%17.74M22.49%13.95M9.48%13.03M
Operating profit -23.25%-84.42M4.24%-18.3M1.23%-23.46M1.41%-19.75M-308.81%-22.91M16.67%-68.5M-7.53%-19.11M6.31%-23.75M-10.55%-20.03M73.25%-5.61M
Net non-operating interest income expense -48.71%3.61M-62.96%600K-58.07%774K-50.82%995K-19.94%1.24M6.17%7.04M1.63%1.62M8.14%1.85M22.16%2.02M-7.35%1.55M
Non-operating interest income -48.71%3.61M-62.96%600K-58.07%774K-50.82%995K-19.94%1.24M6.17%7.04M1.63%1.62M8.14%1.85M22.16%2.02M-7.35%1.55M
Other net income (expense) 114.28%2.58M103.42%692K-2.98%684K-3.39%684K-35.54%515K-1,115.65%-18.04M-3,615.63%-20.25M17.89%705K25.53%708K2,002.63%799K
Special income (charges) --0-------------------20.96M----------------
-Less:Impairment of capital assets --0------------------20.96M----------------
Other non- operating income (expenses) -12.00%2.58M-3.08%692K-2.98%684K-3.39%684K-35.54%515K64.75%2.93M23.96%714K17.89%705K25.53%708K2,002.63%799K
Income before tax 1.59%-78.24M54.94%-17M-3.77%-22M-4.45%-18.07M-549.82%-21.16M-7.73%-79.5M-141.94%-37.74M8.01%-21.2M-8.80%-17.3M83.08%-3.26M
Income tax 164.05%1.39M150.97%1.1M0283K-2.16M-2.16M00
Net income -2.96%-79.62M49.10%-18.11M-3.77%-22M-6.09%-18.35M-549.82%-21.16M-4.80%-77.33M-128.06%-35.57M8.01%-21.2M-8.80%-17.3M83.08%-3.26M
Net income continuous Operations -2.96%-79.62M49.10%-18.11M-3.77%-22M-6.09%-18.35M-549.82%-21.16M-4.80%-77.33M-128.06%-35.57M8.01%-21.2M-8.80%-17.3M83.08%-3.26M
Minority interest income
Net income attributable to the parent company -2.96%-79.62M49.10%-18.11M-3.77%-22M-6.09%-18.35M-549.82%-21.16M-4.80%-77.33M-128.06%-35.57M8.01%-21.2M-8.80%-17.3M83.08%-3.26M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -2.96%-79.62M49.10%-18.11M-3.77%-22M-6.09%-18.35M-549.82%-21.16M-4.80%-77.33M-128.06%-35.57M8.01%-21.2M-8.80%-17.3M83.08%-3.26M
Basic earnings per share 3.03%-1.2850.85%-0.290.00%-0.35-3.45%-0.3-483.33%-0.3528.65%-1.32-78.79%-0.5937.50%-0.3529.27%-0.2988.89%-0.06
Diluted earnings per share 3.03%-1.2850.85%-0.290.00%-0.35-3.45%-0.3-483.33%-0.3528.65%-1.32-78.79%-0.5937.50%-0.3529.27%-0.2988.89%-0.06
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -